Form 4: Adial Pharmaceuticals Director Wendy Young Acquires Shares

Director Wendy B. Young of Adial Pharmaceuticals, Inc. has acquired 36,378 pre-funded warrants for common stock, as detailed in a recent SEC Form 4 filing.

Summary

• Wendy B. Young, a Director at Adial Pharmaceuticals, Inc. (ADIL), reported the acquisition of 36,378 pre-funded warrants on June 12, 2026.
• These warrants are exercisable at a nominal price of $0.001 and represent a beneficial ownership of 36,378 shares of common stock.
• The acquisition was made pursuant to a securities purchase agreement dated June 11, 2026.
• The pre-funded warrants have no expiration date and are exercisable after stockholder approval.
• There is a beneficial ownership limitation of 4.99% of outstanding common stock upon exercise.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while it shows director participation, it's a standard disclosure of warrant acquisition rather than a significant new development.

Positives

• Director Wendy B. Young has increased her beneficial ownership through the acquisition of pre-funded warrants, indicating confidence or a strategic move.
• The acquisition of pre-funded warrants provides a mechanism for future equity participation without immediate significant cash outlay for the warrants themselves.

Negatives

• The filing does not detail the specific financial terms or the total cost of the securities purchase agreement beyond the nominal warrant exercise price.
• The exercise of these warrants is contingent on stockholder approval, which introduces an element of uncertainty.

Risks

• The exercise of pre-funded warrants is subject to a 4.99% beneficial ownership limitation, which could restrict the ability to fully convert all warrants if ownership levels are high.
• Future stock price performance will determine the ultimate value and benefit of these acquired warrants.

Future Outlook

The pre-funded warrants are exercisable at any time after receiving approval of the Issuer's stockholders, indicating a future potential increase in outstanding common stock upon exercise.

Industry Context

StockSavvy.ai notes that the acquisition of pre-funded warrants by a director is a common mechanism for insiders to signal commitment or to facilitate future equity participation, often seen in the biotechnology and pharmaceutical sectors where financing and strategic partnerships are frequent.

Related Party Transactions

• The acquisition of pre-funded warrants by Director Wendy B. Young is a related party transaction, executed under a securities purchase agreement involving the Issuer and the Reporting Person.

Stakeholder Impact

• Shareholders: The potential future issuance of shares upon warrant exercise could lead to dilution, but also indicates insider investment.
• Management: Demonstrates continued engagement and potential future equity stake for Director Wendy B. Young.

Next Steps

• Awaiting stockholder approval for the exercise of pre-funded warrants.
• Potential future exercise of warrants by Wendy B. Young, subject to ownership limitations and approval.

Key Dates

Keywords

Adial Pharmaceuticals, ADIL, Form 4, SEC Filing, Beneficial Ownership, Pre-funded Warrants, Director, Securities Purchase Agreement, Equity